SCHEMBL20740355

SCHEMBL20740355

COC1(CN(CCc2ccccc2)CCc2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.44
OPRK1 P41145 4/20 0.42
OPRM1 P35372 4/20 0.42
OPRD1 P41143 3/20 0.42
AOC3 Q16853 2/20 0.42
DRD3 P35462 2/20 0.40
MCHR1 Q99705 1/20 0.40
CHRM2 P08172 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD1 P21728 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
ADRA1A P35348 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KCNH2 Q12809 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19629908 0.83 CNR2 (0.43) OPRM1AOC3CYP1A2CYP3A4CYP2D6
SCHEMBL15270849 0.73 CALM1 (0.42) OPRM1AOC3L3MBTL1CYP2C19BCHE
SCHEMBL1344100 0.71 OPRK1 (0.65) TAAR1OPRK1OPRM1OPRD1AOC3
SCHEMBL12049808 0.69 OPRK1 (0.63) TAAR1OPRK1OPRM1OPRD1AOC3
SCHEMBL11546029 0.68 OPRM1 (0.76) TAAR1OPRK1OPRM1OPRD1AOC3
SCHEMBL443493 0.68 OPRM1 (0.69) TAAR1OPRK1OPRM1OPRD1AOC3
SCHEMBL9653111 0.67 TAAR1 (0.44) TAAR1OPRK1OPRM1OPRD1AOC3
SCHEMBL27767395 0.67 TACR1 (0.42) OPRM1SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL552965 0.66 DRD3 (0.71) TAAR1OPRK1OPRM1OPRD1AOC3
SCHEMBL828470 0.66 TAAR1 (0.58) TAAR1OPRM1AOC3DRD3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-06-06 US disclosed
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-09-12 US disclosed
EP-3444250-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2019-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF FGFR4, FGFR1, FGFR2 TAAR1 4874/4885OPRK1 4438/4885OPRM1 4522/4885
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof FGFR4, FGFR1, FGFR2 TAAR1 4874/4885OPRK1 4438/4885OPRM1 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.